Sistema de Salut de Catalunya
Institut Català de la Salut
[Salvador F, Molina I] Servei de Malalties Infeccioses, Vall d’Hebron Hospital Universitari, Barcelona, Spain. PROSICS Barcelona, Spain. [Lucas-Dato A] Internal Medicine Department, Hospital Vega Baja, 03314 Orihuela, Spain. [Roure S] Infectious Diseases Department, North Metropolitan International Health Unit, Germans Trias i Pujol University Hospital, PROSICS North Metropolitan, 08916 Badalona, Spain. [Arsuaga M] Tropical Medicine Unit, Infectious Diseases Department, La Paz-Carlos III University Hospital, 28046 Madrid, Spain. [Pérez-Jacoiste A] Internal Medicine Department, Hospital Universitario 12 de Octubre, 28041 Madrid, Spain. [García-Rodríguez M] Infectious Diseases Department, Hospital General Universitario de Valencia, 46014 Valencia, Spain
Vall d'Hebron Barcelona Hospital Campus
2022-03-11T13:14:36Z
2022-03-11T13:14:36Z
2021-07
Strongyloides stercoralis; Immunosupressió; Ivermectina
Strongyloides stercoralis; Inmunosupresión; Ivermectina
Strongyloides stercoralis; Immunosuppression; Ivermectin
Strongyloidiasis affects an estimated 600 million people worldwide, especially in tropical and subtropical areas. Single-dose ivermectin treatment has shown to be effective among immunocompetent patients with uncomplicated strongyloidiasis. Here, we present the protocol of the ImmunoStrong study, a prospective observational study aiming to evaluate the effectiveness and safety of a single-dose ivermectin for treatment of uncomplicated strongyloidiasis in immunosuppressed patients. The secondary objectives are to assess accuracy of molecular techniques for the follow-up of these patients and to determine the population pharmacokinetics of ivermectin. The information retrieved by this study will cover relevant information gaps in the strongyloidiasis management among immunosuppressed patients.
The present work was supported by the 2020 Research Grant from the Spanish Society of Infectious Diseases and Clinical Microbiology (SEIMC).
Article
Published version
English
Malalties parasitàries - Tractament; Avaluació de resultats (Assistència sanitària); DISEASES::Parasitic Diseases::Helminthiasis::Nematode Infections::Secernentea Infections::Rhabditida Infections::Strongyloidiasis; Other subheadings::Other subheadings::Other subheadings::/drug therapy; ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT::Diagnosis::Prognosis::Treatment Outcome; ENFERMEDADES::enfermedades parasitarias::helmintiasis::infecciones por nematodos::infecciones por Secernentea::infecciones por Rhabditida::estrongiloidiasis; Otros calificadores::Otros calificadores::Otros calificadores::/farmacoterapia; TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS::diagnóstico::pronóstico::resultado del tratamiento
MDPI
Pathogens;10(7)
https://doi.org/10.3390/pathogens10070812
Attribution 4.0 International
http://creativecommons.org/licenses/by/4.0/
Articles científics - HVH [3440]
